Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.

Scientific microscope with visual representation of DNA helix

Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models

September 7, 2022

Trethera and UCLA published peer-reviewed findings showing that TRE‑515 selectively inhibits autoreactive lymphocytes in mouse models of multiple sclerosis, resulting in improved symptoms without impairing healthy immune function.

Read More 

Trethera Receives U.S. Patent Office Notice of Allowance Covering TRE-515 Structural Claims, Extending Protections to Late 2041



August 17, 2022

Trethera has been issued a USPTO Notice of Allowance for TRE‑515’s structural composition of matter patent, extending its U.S. market exclusivity through November 2041. The patent covers the unique TRE‑515 chemical structure across therapeutic areas.

Read More 

Trethera Phase 1 Solid Tumors Trial Dose Escalates To Fourth Cohort After Safety Review Committee Determines Primary Trial Endpoint Achieved



June 1, 2022

Trethera’s Phase 1a trial of TRE‑515 in solid tumors reached the fourth dose cohort following independent safety review. Results showed favorable tolerability, no dose‑limiting toxicity, stable disease in 50% of early evaluable patients, and supportive PK data.

Read More 

Trethera Scientific Founder Dr. Caius Radu To Present Research At Los Angeles Bioscience Ecosystem Summit 2022



May 19, 2022

Dr. Caius Radu, Trethera’s scientific founder and UCLA professor, will present TRE‑515’s first‑in‑human deoxycytidine kinase inhibitor research at LABEST 2022. The presentation highlights TRE‑515’s dual potential in cancer and autoimmune disease treatment.

Read More 

Trethera Announces Completion of $3.8 Million Seed Funding Round From Current Investors



May 11, 2022

Trethera closed a $3.8M follow-on seed funding from current investors to fuel its clinical-stage programs, including TRE‑515’s orphan-designated development in oncology and autoimmune conditions like MS and optic neuritis.

Read More 